Category: General Prostate

Let’s start with cells. Animals, including humans, are made up of millions, billions, or even (in the case of humans) trillions of cells. We know from basic biology that cells grow and divide, and in the process each new cell contains a copy of its entire genome. However... keep reading

Thanks to PSA screening and early detection, most prostate cancer is diagnosed while it is still contained in the prostate gland. This implies favorable odds that any whole-gland treatment is potentially curative... keep reading

I have written several blogs on external beam radiation for prostate cancer along with its side effects. Radiation is a good choice for the right patient. As with all prostate cancer treatments, it is essential to match a treatment with an individual’s cancer because many factors go into the choice... keep reading

What do these three things have in common: Benign prostatic hyperplasia or BPH (non-cancerous prostate enlargement),male pattern baldness and aggressive prostate cancer that is potentially lethal? The first—and most obvious—answer is that they are all risks that men face with aging. The second less obvious answer is... keep reading

A PSMA PET/CT scan (or simply PSMA PET) like the one described below that incorporates the radioisotope Gallium-68, is the most sensitive method to detect metastatic prostate cancer (mPCa). PSMA PET has thus quickly gained wide use, including evaluating how well a patient’s mPCa is responding to therapy... keep reading

An exciting new imaging modality called PSMA PET/CT has entered the global prostate cancer diagnosis scene. When a short-lived positron emitting isotope called Gallium 68 is bonded to a molecule that is attractive to a specific protein found abundantly on the surface of prostate cancer (PCa) cells, the cells “light up” on PET/CT scans. keep reading

Urologist Bert Vorstman MD continues to be “a keen observer of the state of prostate cancer.” 1 During an interview for the American Society of Clinical Oncology (ASCO), he made some observations in which he did not mince words... keep reading

Do you ever regret a decision that turns out to have a bad outcome? This is the situation for many prostate cancer (PCa) patients who chose radical prostatectomy (RP). A 2017 study found that 15% of PCa patients regret their treatment choice, with twice as many patients ruing the day they opted for RP or keep reading

The tug-of-war continues between prostate cancer patients who want to be treated with proton beam therapy (PBT) vs. their insurance companies. As you can read from the blog below, payers are denying PCa coverage due to the high cost of the treatment coupled with lack of evidence showing superiority over conventional radiation therapies... keep reading

Here’s the back story: there is a British clinician/researcher, Hashim Ahmed, whose published articles I respect. His publications often include Mark Emberton, another esteemed British urologist, so when both names turn up in the same group of authors on a published paper, it grabs my attention. This is the case with a 2020 multicenter study keep reading